Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)

NCT04950127 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04950127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
August 27, 2021
Completion date
December 20, 2024
Enrollment
238 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pruritus